Biotech’s Next 2x Trade?

China biotech stocks up +39% YoY...

AI and geopolitics dominate the noise—but biotech may be the real opportunity.

1. U.S. small/mid-caps trade at just 1.2x cash, pricing in deep pessimism.

2. Meanwhile, China’s 2820.HK is up 39% YoY on strong state support.

This report sets up two equity trades: a possible mean-reversion play in the West, and a long-term re-rating in the East.

Source: Trevor Scott

Note: The author(s) hold BTC and ETH at the time of writing ( disclaimer).

Key Report Insights:

1. East vs. West: Biotech is splitting, with China decoupling from U.S. weakness.

2. Valuation Breakdown: U.S. biotech trades near all-time lows at just 1.2x cash.

3. China Leads Trials: China now tops the world in new clinical trial launches.

4. Policy-Driven Growth: State support and deep talent fuel China’s biotech ascent.

5. U.S. Headwinds Mount: NIH cuts & trade risk continue to weigh on U.S. names.

📈 We flagged biotech stock VKTX at $19.98—now up 30%+. Join 250+ investors spotting the next breakout.